TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

ProKidney Presents Full Results from the Phase 2 REGEN-007 Trial of Rilparencel at the American Society of Nephrology Kidney Week 2025

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Prokidney Corp.
ProKidney Presents Full Results from the Phase 2 REGEN-007 Trial of Rilparencel at the American Society of Nephrology Kidney Week 2025

ProKidney presented Phase 2 trial results showing rilparencel potentially slows chronic kidney disease progression in diabetic patients, with statistically significant improvements in estimated glomerular filtration rate (eGFR) slope and no serious adverse events.

Insights
PROK   positive

Positive trial results demonstrating potential efficacy of rilparencel, advancement of Phase 3 clinical trial, and promising data for treating chronic kidney disease